<DOC>
	<DOCNO>NCT00207402</DOCNO>
	<brief_summary>Genotype 1 hepatitis C virus ( HCV ) patient respond ( lose virus treatment ) relapse ( virus go away treatment come back treatment stop ) treatment least twelve week pegylated ( long-acting ) interferon ribavirin consider study . There two purpose study : first , determine rosiglitazone , medicine use treat diabetes , affect HCV viral load ; second , determine treatment insulin resistance rosiglitazone prior therapy HCV improve sustain virologic response ( loss virus continue beyond six month completion HCV therapy ) HCV therapy .</brief_summary>
	<brief_title>Infergen , Ribavirin &amp; Avandia Previous Relapsers Nonresponders Pegylated Interferon Ribavirin</brief_title>
	<detailed_description>This study demonstrate efficacy treat insulin resistance rosiglitazone CHC , genotype 1 patient fail previous treatment pegylated interferon ribavirin . Pre-treatment rosiglitazone may become new standard care prior HCV therapy patient insulin resistant , increase chance achieve SVR interferon alfacon-1 combination therapy decrease morbidity mortality associate chronic hepatitis C .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Participants willing give write informed consent able adhere dose visit schedule . Adult participants 18 year age old either gender race . Participants 65 year age must generally good health . HCVantibody ( Ab ) HCVRNA positive polymerase chain reaction ( PCR ) least 6 month . Serum positive HCVRNA PCR assay . Subjects must previous nonresponders relapsers pegylated interferon ribavirin therapy . Liver biopsy within 24 month prior enrollment protocol . Compensated liver disease follow minimum hematological , biochemical , serologic criterion Screening Visit ( WNL = within normal limit ) : Hemoglobin value &lt; 12 gm/dL female &lt; 13 gm/dL male . White blood cell ( WBC ) &lt; 3,000/mm3 Neutrophil count &lt; 1,500/mm3 Platelets &lt; 65,000/mm3 Direct bilirubin , within 20 % upper limit normal ( ULN ) Indirect bilirubin , ( WNL ) ( unless nonhepatitis related factor Gilbert 's disease explain indirect bilirubin rise . In case indirect bilirubin must &lt; 3.0 mg/dL [ &lt; 51.3 Âµmol/L ] ) . Albumin &gt; 3 gm/dL Serum creatinine &lt; 20 % ULN Thyroid stimulate hormone ( TSH ) WNL Alpha fetoprotein value &lt; 100 ng/mL . Reconfirmation documentation sexually active female subject childbearing potential practicing adequate contraception treatment period 6 month follow last dose study medication . Female subject must breastfeed . Reconfirmation sexually active male subject practice two acceptable method contraception treatment period 6 month follow last dose study medication . Inability unwillingness provide inform consent abide requirement study Participants insulin exclude . Participants metformin another thiazolidinedione must threemonth washout period consider study . Women pregnant breastfeeding Males whose female partner pregnant No thiazolidinedione liver biopsy and/or entire study ( subject randomize receive rosiglitazone study ) Hepatitis C nongenotype 1 Suspected hypersensitivity interferon , ribavirin , rosiglitazone Any cause liver disease chronic hepatitis C , insulin resistance , nonalcoholic fatty liver disease ( NAFLD ) , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Coinfection hepatitis B virus ( HBV ) [ serum hepatitis B surface antigen ( HBsAg ) positive ] Wilson 's disease Autoimmune hepatitis Alcoholic liver disease ( consumption great 2 drink day average ) Drugrelated liver disease Any condition would prevent subject liver biopsy . Hemoglobinopathies could potentially compromise patient safety ( e.g. , beta thalassemia major , sickle cell disease ) Evidence advance liver disease Participants organ transplant cornea hair transplant Any known preexist medical condition could interfere subject 's participation completion protocol : Preexisting psychiatric condition , especially severe depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt . Participants history mild depression may consider entry protocol provide pretreatment assessment subject 's mental status support participant clinically stable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>